Georgia Research Alliance Subscribes To Celera Discovery System
Rockville, MD - February 11, 2002
Celera Genomics (NYSE:CRA), an Applera Corporation business, announced today it signed a multi-year agreement with the Georgia Research Alliance, allowing academic researchers in Georgia access to Celera’s database products. Subscribers will have access to Celera's database information and research tools through the Celera Discovery System™. The eligible institutions under the Georgia Research Alliance are: Clark Atlanta University, Emory University, Georgia Institute of Technology, Georgia State University, Medical College of Georgia, Morehouse School of Medicine, The University of Georgia, Athens, and Mercer University. Financial terms of the agreement were not disclosed.
The Celera Discovery System is an integrated, web-based platform that enables users to leverage Celera’s computational tools, super-computing power, genomic and biological data to advance the discovery process for researchers worldwide.
About Georgia Research Alliance
Founded in 1990, the Georgia Research Alliance represents a partnership of the state's research universities, the business community and state government. Its mission is to foster economic development within Georgia by developing and leveraging the research capabilities of the research universities within the state and to assist and develop scientific and technology-based industry, commerce, and business.
Research programs are concentrated in three strategic areas; advanced communications, biotechnology and environmental technologies. Centers formed around each of these technology areas help promote cross-disciplinary and cross-institutional research and facilitate the transfer of technology into applications that are relevant to the marketplace.
Leaders in academia, business, and public office are working diligently to leverage the research capabilities at the state's universities through construction of new research facilities, installation of state-of-the-art equipment and instrumentation, and through the recruitment of leading scholars at The University of Georgia, the Medical College of Georgia, Emory University, Clark Atlanta University, the Georgia Institute of Technology and Georgia State University.
About Applera Corporation and Celera Genomics
Applera Corporation comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, is engaged principally in integrating advanced technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera’s businesses are its online information business and its therapeutics discovery business. The online information business is a leading provider of information based on the human genome and other biological and medical information. Through the therapeutic discovery business, Celera intends to leverage its genomic and proteomic capabilities to identify drug targets and diagnostic marker candidates, and to discover novel therapeutic candidates. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. Celera Diagnostics, a joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostics tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923. Information about Celera is available on the World Wide Web at www.celera.com.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.